- Home
- DAWN vs ELVN Comparison
DAWN vs ELVN Comparison
Compare DAWN & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAWN | ELVN |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DAWN | ELVN |
|---|---|---|
| Price | $21.52 | $35.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $24.43 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 2.7M | 646.0K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $158,182,000.00 | N/A |
| Revenue This Year | $55.03 | N/A |
| Revenue Next Year | $28.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.60 | N/A |
| 52 Week Low | $5.64 | $14.79 |
| 52 Week High | $21.53 | $48.53 |
Technical Indicators
Market Signals| Indicator | DAWN | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 80.29 | 37.42 |
| Support Level | $10.30 | $19.19 |
| Resistance Level | N/A | $40.62 |
| Average True Range (ATR) | 0.03 | 1.96 |
| MACD | -0.28 | -0.71 |
| Stochastic Oscillator | 90.91 | 19.15 |
Price Performance
Historical ComparisonAbout DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.